Wednesday, September 10, 2008

Slowing Generic Erosion: Fosamax Case

Interesting article on how to stem generic erosion.

"As plans look at cost controls, they will start asking what the "value" is of new therapies relative to generic alternatives. In other words, is the incremental benefit worth the price? Almost a third expect a 30 percent or greater risk reduction to differentiate from current therapies. The bar for access is not equal to but better."